Prescribing direct-acting oral anticoagulants - Mind the evidence gap.
Br J Clin Pharmacol
; 88(11): 4724-4731, 2022 11.
Article
en En
| MEDLINE
| ID: mdl-35771028
ABSTRACT
Direct-acting oral anticoagulants (DOACs) are licensed for the prevention of thromboembolism in non-valvular atrial fibrillation, amongst other indications. Prescribers use information derived from the summary of product characteristics which is based on the key trials supporting the DOAC's market authorisation. However, prescribers may not be aware of the limitations within these trials regarding underrepresentation of patient populations commonly encountered in clinical practice and how this may adversely impact them. This review highlights the gaps in the licensing evidence using four clinical vignettes that explore prescribing challenges in older adults, female patients, patients with obesity and patients from non-Europid ethnic backgrounds.
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Fibrilación Atrial
/
Tromboembolia
/
Accidente Cerebrovascular
Límite:
Aged
/
Female
/
Humans
Idioma:
En
Año:
2022
Tipo del documento:
Article